Vascular Dementia

JT O. T. A,“Vascular dementia,”. Lancet (London, England). 2015;386(10004):1698-706. DOI:https://doi.org/10.1016/S0140-6736(15)00463-8

Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, vd. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(1):227-76. https://doi.org/10.1161/STR.0000000000000024

Bots ML, Breteler MMB, Hofman A, Grobbee DE, Van Swieten JC, van Gijn J, vd. Cerebral white matter lesions and atherosclerosis in the Rotterdam Study. The Lancet. 1993;341(8855):1232-7. https://doi.org/10.1016/0140-6736(93)91144-BGet rights and content

Prabhakaran S, Wright CB, Yoshita M, Delapaz R, Brown T, DeCarli C, vd. Prevalence and determinants of subclinical brain infarction: the Northern Manhattan Study. Neurology. 2008;70(6):425-30. DOI: https://doi.org/10.1212/01.wnl.0000277521.66947.e5

Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer’s & dementia. 2013;9(1):63-75. https://doi.org/10.1016/j.jalz.2012.11.007

Savva GM, Stephan BC, Group ASVDSR. Epidemiological studies of the effect of stroke on incident dementia: a systematic review. Stroke. 2010;41(1):e41-6. https://doi.org/10.1161/STROKEAHA.109.559880

Zhu YC, Dufouil C, Tzourio C, Chabriat H. Silent brain infarcts: a review of MRI diagnostic criteria. Stroke. 2011;42(4):1140-5. https://doi.org/10.1161/STROKEAHA.110.600114

Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. The Lancet Neurology. 2005;4(11):752-9. DOI:https://doi.org/10.1016/S1474-4422(05)70221-0

Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. The Lancet Neurology. 2009;8(11):1006-18. DOI:https://doi.org/10.1016/S1474-4422(09)70236-4

Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, vd. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. The Lancet Neurology. 2008;7(8):683-9. DOI:https://doi.org/10.1016/S1474-4422(08)70143-1

Bir SC, Khan MW, Javalkar V, Toledo EG, Kelley RE. Emerging concepts in vascular dementia: a review. Journal of Stroke and Cerebrovascular Diseases. 2021;30(8):105864. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105864

Ramos AR, Dib SI, Wright CB. Vascular dementia. Current translational geriatrics and experimental gerontology reports. 2013;2:188-95. DOI 10.1007/s13670-013-0054-5

Vasdekis SN, Tsivgoulis G, Athanasiadis D, Andrikopoulou A, Voumvourakis K, Lazaris AM, vd. Cerebrovascular reacivity assessment in patients with carotid artery disease: a combined TCD and NIRS study. Journal of Neuroimaging. 2012;22(3):261-5. https://doi.org/10.1111/j.1552-6569.2011.00595.x

Teodorczuk A, O’Brien JT, Firbank MJ, Pantoni L, Poggesi A, Erkinjuntti T, vd. White matter changes and late-life depressive symptoms: longitudinal study. The British Journal of Psychiatry. 2007;191(3):212-7. doi:10.1192/bjp.bp.107.036756

Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. The Lancet Neurology. 2009;8(7):643-53. DOI:https://doi.org/10.1016/S1474-4422(09)70127-9

Dwyer R, Skrobot OA, Dwyer J, Munafo M, Kehoe PG. Using Alzgene-like approaches to investigate susceptibility genes for vascular cognitive impairment. Journal of Alzheimer’s Disease. 2013;34(1):145-54. DOI: 10.3233/JAD-121069

Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80(4):844-66. http://dx.doi.org/10.1016/j.neuron.2013.10.008

Liu H, Yang M, Li GM, Qiu Y, Zheng J, Du X, vd. The MTHFR C677T polymorphism contributes to an increased risk for vascular dementia: a meta-analysis. Journal of the neurological sciences. 2010;294(1-2):74-80. https://doi.org/10.1016/j.jns.2010.04.001

Gold G, Bouras C, Canuto A, Bergallo MF, Herrmann FR, Hof PR, vd. Clinicopathological validation study of four sets of clinical criteria for vascular dementia. American Journal of Psychiatry. 2002;159(1):82-7. https://doi.org/10.1176/appi.ajp.159.1.82

Kalaria RN. Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer’s disease. Acta neuropathologica. 2016;131(5):659-85. DOI 10.1007/s00401-016-1571-z

Stebbins GT, Nyenhuis DL, Wang C, Cox JL, Freels S, Bangen K, vd. Gray matter atrophy in patients with ischemic stroke with cognitive impairment. Stroke. 2008;39(3):785-93. https://doi.org/10.1161/STROKEAHA.107.507392

Ylikoski R, Jokinen H, Andersen P, Salonen O, Madureira S, Ferro J, vd. Comparison of the Alzheimer’s Disease Assessment Scale Cognitive Subscale and the vascular dementia assessment scale in differentiating elderly individuals with different degrees of white matter changes. Dementia and geriatric cognitive disorders. 2007;24(2):73-81. https://doi.org/10.1159/000103865

Lees R, Selvarajah J, Fenton C, Pendlebury ST, Langhorne P, Stott DJ, vd. Test accuracy of cognitive screening tests for diagnosis of dementia and multidomain cognitive impairment in stroke. Stroke. 2014;45(10):3008-18. https://doi.org/10.1161/STROKEAHA.114.005842

Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. Jama. 2002;288(12):1475-83. doi:10.1001/jama.288.12.1475

Santos MAO, Bezerra LS, Correia C da C, Bruscky IS. Neuropsychiatric symptoms in vascular dementia: epidemiologic and clinical aspects. Dementia & Neuropsychologia. 2018;12:40-4. https://doi.org/10.1590/1980-57642018dn12-010006

Panza F, Frisardi V, Capurso C, D’Introno A, Colacicco AM, Imbimbo BP, vd. Late-life depression, mild cognitive impairment, and dementia: possible continuum? The American Journal of Geriatric Psychiatry. 2010;18(2):98-116. https://doi.org/10.1097/JGP.0b013e3181b0fa13

Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study. Journal of the American Geriatrics Society. 2010;58(2):330-7. https://doi.org/10.1111/j.1532-5415.2009.02680.x

Jokinen H, Lipsanen J, Schmidt R, Fazekas F, Gouw AA, Van Der Flier WM, vd. Brain atrophy accelerates cognitive decline in cerebral small vessel disease: the LADIS study. Neurology. 2012;78(22):1785-92. DOI: https://doi.org/10.1212/WNL.0b013e3182583070

Zarow C, Wang L, Chui HC, Weiner MW, Csernansky JG. MRI shows more severe hippocampal atrophy and shape deformation in hippocampal sclerosis than in Alzheimer’s disease. International Journal of Alzheimer’s Disease. 2011;2011. https://doi.org/10.4061/2011/483972

Marchant NL, Reed BR, DeCarli CS, Madison CM, Weiner MW, Chui HC, vd. Cerebrovascular disease, beta-amyloid, and cognition in aging. Neurobiology of aging. 2012;33(5):1006-e25. https://doi.org/10.1016/j.neurobiolaging.2011.10.001

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, vd. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Jama. 2009;302(4):385-93. doi:10.1001/jama.2009.1064

Jagtap A, Gawande S, Sharma S. Biomarkers in vascular dementia: A recent update. Biomarkers and Genomic Medicine. 2015;7(2):43-56. https://doi.org/10.1016/j.bgm.2014.11.001

Yusuf S, Sleight P, Pogue J ft, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The New England journal of medicine. 2000;342(3):145-53. https://doi.org/10.1056/nejm200001203420301

Vieira JR, Elkind MS, Moon YP, Rundek T, Boden-Albala B, Paik MC, vd. The metabolic syndrome and cognitive performance: the Northern Manhattan Study. Neuroepidemiology. 2011;37(3-4):153-9. https://doi.org/10.1159/000332208

Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, vd. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. The lancet. 2002;360(9346):1623-30. DOI:https://doi.org/10.1016/S0140-6736(02)11600-X

Erkinjuntti T, Gauthier S, Bullock R, Kurz A, Hammond G, Schwalen S, vd. Galantamine treatment in Alzheimer’s disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). Journal of psychopharmacology. 2008;22(7):761-8. ttps://doi.org/10.1177/0269881107083

Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834-9. https://doi.org/10.1161/01.STR.0000020094.08790.49

Pantoni L, Basile AM, Pracucci G, Asplund K, Bogousslavsky J, Chabriat H, vd. Impact of age-related cerebral white matter changes on the transition to disability–the LADIS study: rationale, design and methodology. Neuroepidemiology. 2005;24(1-2):51-62. https://doi.org/10.1159/000081050

Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews. 2013;(1). https://doi.org/10.1002/14651858.CD008900.pub2